Selvita Valuation
Is 787 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 787 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 787 (€11.7) is trading below our estimate of fair value (€23.71)
Significantly Below Fair Value: 787 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 787?
Key metric: As 787 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 787's PE Ratio? | |
|---|---|
| PE Ratio | 20.7x |
| Earnings | zł47.40m |
| Market Cap | zł982.02m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.6x |
| Enterprise Value/EBITDA | 52.4x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does 787's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 62.8x | ||
GXI Gerresheimer | 21.7x | 21.7% | €2.5b |
1SXP SCHOTT Pharma KGaA | 25.7x | 15.9% | €3.9b |
SRT3 Sartorius | 187.6x | 36.4% | €13.1b |
PSG PharmaSGP Holding | 16.1x | 14.6% | €292.6m |
787 Selvita | 20.7x | 15.0% | €982.0m |
Price-To-Earnings vs Peers: 787 is good value based on its Price-To-Earnings Ratio (20.7x) compared to the peer average (62.8x).
Price to Earnings Ratio vs Industry
How does 787's PE Ratio compare vs other companies in the European Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 787 is good value based on its Price-To-Earnings Ratio (20.7x) compared to the European Life Sciences industry average (37.1x).
Price to Earnings Ratio vs Fair Ratio
What is 787's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 20.7x |
| Fair PE Ratio | 12.5x |
Price-To-Earnings vs Fair Ratio: 787 is expensive based on its Price-To-Earnings Ratio (20.7x) compared to the estimated Fair Price-To-Earnings Ratio (12.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.70 | €15.90 +35.9% | 11.1% | €18.08 | €13.32 | n/a | 6 |
| Nov ’25 | €12.00 | €15.90 +32.5% | 11.1% | €18.08 | €13.32 | n/a | 6 |
| Oct ’25 | €13.10 | €16.32 +24.6% | 10.4% | €18.44 | €13.59 | n/a | 6 |
| Sep ’25 | €15.14 | €16.59 +9.6% | 7.7% | €18.40 | €14.66 | n/a | 6 |
| Aug ’25 | €15.36 | €16.59 +8.0% | 7.7% | €18.40 | €14.66 | n/a | 6 |
| Jul ’25 | €15.50 | €16.59 +7.1% | 7.7% | €18.40 | €14.66 | n/a | 6 |
| Jun ’25 | €15.08 | €16.59 +10.0% | 7.7% | €18.40 | €14.66 | n/a | 6 |
| May ’25 | €15.36 | €15.98 +4.0% | 8.5% | €18.23 | €14.52 | n/a | 5 |
| Apr ’25 | €14.14 | €16.72 +18.2% | 7.3% | €18.38 | €15.18 | n/a | 5 |
| Mar ’25 | €13.26 | €16.26 +22.6% | 10.5% | €18.24 | €13.44 | n/a | 5 |
| Feb ’25 | €13.32 | €16.26 +22.1% | 10.5% | €18.24 | €13.44 | n/a | 5 |
| Jan ’25 | €13.56 | €18.04 +33.1% | 26.5% | €27.20 | €13.43 | n/a | 5 |
| Dec ’24 | €13.20 | €18.04 +36.7% | 26.5% | €27.20 | €13.43 | n/a | 5 |
| Nov ’24 | €13.40 | €18.37 +37.1% | 22.3% | €26.41 | €14.84 | €12.00 | 5 |
| Oct ’24 | €12.60 | €18.26 +44.9% | 20.5% | €25.33 | €14.23 | €13.10 | 5 |
| Sep ’24 | €14.44 | €18.98 +31.4% | 20.2% | €26.26 | €14.97 | €15.14 | 5 |
| Aug ’24 | €16.62 | €18.98 +14.2% | 20.2% | €26.26 | €14.97 | €15.36 | 5 |
| Jul ’24 | €15.14 | €18.98 +25.3% | 20.2% | €26.26 | €14.97 | €15.50 | 5 |
| Jun ’24 | €16.42 | €18.79 +14.4% | 18.6% | €25.64 | €15.93 | €15.08 | 5 |
| May ’24 | €16.34 | €18.79 +15.0% | 18.6% | €25.64 | €15.93 | €15.36 | 5 |
| Apr ’24 | €16.60 | €20.07 +20.9% | 17.7% | €25.11 | €15.60 | €14.14 | 5 |
| Mar ’24 | €16.92 | €20.41 +20.6% | 14.7% | €24.90 | €16.32 | €13.26 | 5 |
| Feb ’24 | €18.14 | €19.38 +6.9% | 10.3% | €21.81 | €16.43 | €13.32 | 5 |
| Jan ’24 | €17.60 | €19.38 +10.1% | 10.3% | €21.81 | €16.43 | €13.56 | 5 |
| Dec ’23 | €17.20 | €19.38 +12.7% | 10.3% | €21.81 | €16.43 | €13.20 | 5 |
| Nov ’23 | €17.76 | €19.27 +8.5% | 10.5% | €21.72 | €16.37 | €13.40 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Regeneron Pharmaceuticals
US$81.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$713.60
7D
-8.3%
1Y
-2.5%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-2.6%
1Y
86.3%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.35
7D
-4.5%
1Y
-2.3%